T1	Participants 0 33	Sinemet CR in Parkinson's disease
T2	Participants 48 87	a controlled release carbidopa/levodopa
T3	Participants 205 278	clinical benefits and adverse effects were noted with the two medications
T4	Participants 288 353	significantly less frequent dosing was necessary with Sinemet CR.
